Impact of brodalumab treatment on psoriasis symptoms and health‐related quality of life: use of a novel patient‐reported outcome measure, the Psoriasis Symptom Inventory

Abstract

BackgroundPsoriasis symptoms have a significant negative impact on health-related quality of life, impairing physical functioning and well-being.ObjectiveTo evaluate the impact of brodalumab, a human anti-interleukin-17R monoclonal antibody, on psoriasis symptom severity as measured by a novel patient-reported outcome measure, the Psoriasis Symptom Inventory, and dermatology-specific health-related quality of life as measured by the Dermatology Life Quality Index (DLQI).MethodsThis was a secondary analysis of a phase II, randomized, double-blind, placebo-controlled clinical study of patients with moderate-to-severe psoriasis (n = 198) treated with brodalumab or placebo. This analysis assessed Psoriasis Symptom Inventory scores and DLQI scores over time. Analyses were conducted on all patients who were randomized and received one or more injections of the study drug according to intention to treat using last observation carried forward to impute missing data.ResultsAt week 12, subjects in the brodalumab groups had significant improvements in mean Psoriasis Symptom Inventory total scores [8·5 (70 mg), 15·8 (140 mg), 16·2 (210 mg) and 12·7 (280 mg)] compared with placebo (4·8). Mean improvements in DLQI were clinically meaningful (≥ 5·7) in the brodalumab groups (6·2, 9·1, 9·6 and 7·1, respectively) and significantly greater than placebo (3·1). Improvements in Psoriasis Symptom Inventory were observed as early as week 2 and in DLQI by week 4. All eight Psoriasis Symptom Inventory item scores improved significantly among the brodalumab groups by week 12.ConclusionsResults were from a single randomized clinical trial and may not generalize to broader patient populations. However, treatment with brodalumab provided significant improvement in psoriasis symptoms in patients with moderate-to-severe psoriasis.

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

“…From a patient perspective, the importance of PROs in psoriasis management should not be understated. Improvements in PROs are not only associated with better HRQoL for the patient but also have a positive secondary impact on the lives of patients’ relatives and partners . Nevertheless, studies on patient perspectives suggest a disconnect with physicians regarding the extent of disease that patients experience .…”

Itch: an under‐recognized problem in psoriasis

“…Such clinical data may form an important foundation to support the evidence‐based care of psoriasis patients with itch symptoms. The following discussion reviews the itch effect of topical agents, systemics and biologics, and phototherapy, as revealed in recent studies (Table ) . Itch relief remains a significant gap in the treatment landscape for psoriasis, as not all patients are able to achieve control of this symptom, even with cleared or markedly improved skin.…”

Clinical Efficacy and Safety of Anti-IL-17 Agents for the Treatment of Patients with Psoriasis

“…These observations provided the basis for development of biological agents targeting IL-17 signaling pathways. Anti-IL-17 agents, which include secukinumab, ixekizumab and brodalumab, have proved highly effective in treating psoriasis [14][15][16][17][18][19][20][21][24][25][26].…”